Age-related macular degeneration
Conditions
Interventions
None listed
Sponsors
Department of Ophthalmology, Juntendo University Faculty of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The subjects are patients diagnosed with wet-age-related macular degeneration. Subjects aged 20 years or older at the time of informed consent. Subjects who received sufficient informed consent before participating in this study, and after sufficient understanding, obtained the voluntary written consent of the subjects themselves. There is no target number of recruitment by gender.
Exclusion criteria
Exclusion criteria: Those who are judged by the principal investigator to be inappropriate as research subjects. Those who are judged to have difficulty in going to the hospital on a regular basis. Those who have an intra-ocular inflammation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| This observational study is planned for 2 years after administration of brolucizumab. An interim evaluation will be made one year after the administration. The main outcome are visual acuity and the retinal status. | — |
Secondary
| Measure | Time frame |
|---|---|
| The required number of brolucizumab administration during the observation period. Background factors (age, gender, classification of AMD, past history, and lifestyle) effect on thetherapeutic effect of brolucizumab. | — |
Countries
Japan
Contacts
Public ContactHirakata Toshiaki
Juntendo University Faculty of Medicine Department of Ophthalmology
Outcome results
None listed